RecruitingNCT07379463
Amino Acid Transporter System PET/CT Imaging in AATS-Related Diseases
Sponsor
Tianjin Medical University
Enrollment
500 participants
Start Date
Aug 29, 2013
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the potential usefulness of 11C/18F-MET/FET positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.
Eligibility
Min Age: 18 YearsMax Age: 90 Years
Inclusion Criteria4
- adult patients (aged 18 years or order);
- patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);
- patients who had scheduled AATS PET/CT scan;
- patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion Criteria3
- patients with non-malignant lesions;
- patients with pregnancy;
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TEST11C/18F-MET/FET
Each subject receive a single intravenous injection of 11C/18F-MET/FET, and undergo PET/CT imaging within the specificed time
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07379463
Related Trials
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
NCT074161881 location
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
NCT074447231 location
Natural History Study of Parathyroid Disorders
NCT049699261 location
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT0553813079 locations
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT073265665 locations